According to filings with the U.S. Securities and Exchange Commission, NexImmune is raising $3,670,000.00 in new funding. About NexImmune: NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

To learn more about NexImmune, visit http://neximmune.com/

Contact:
Kristi Jones, Chief Executive Officer
301-825-9810

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.